Securities code: 301080 securities abbreviation: Acrobiosystems Co.Ltd(301080) Announcement No.: 2022-003 Acrobiosystems Co.Ltd(301080)
About participating in the investment of Tianjin Kangcheng Bain equity investment fund
Announcement of partnership (limited partnership)
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special tips:
1. The agreement on this investment in the partnership has not been signed, and the investment fund has not yet fulfilled the registration and filing procedures, so there are certain uncertain factors. The company will disclose the progress of this investment in a timely manner in strict accordance with relevant regulations. Please pay attention to the investment risks.
2. The investment in Tianjin Kangcheng Bain equity investment fund partnership (limited partnership) will not have a great impact on the production and operation of the company this year.
1、 Overview of foreign investment
Acrobiosystems Co.Ltd(301080) (hereinafter referred to as “the company”) held the 13th meeting of the first board of directors on January 24, 2022. The meeting deliberated and adopted the proposal on participating in investment in Tianjin Kangcheng Bain equity investment fund partnership (limited partnership) with 7 affirmative votes, 0 negative votes and 0 abstention votes, It is agreed that the company will participate in the investment of Tianjin Kangcheng Baien equity investment fund partnership (limited partnership) (hereinafter referred to as “partnership”) (tentative name, which shall be subject to the subsequent industrial and commercial registration). The total amount of capital contribution to be subscribed by the fund is 150 million yuan, and the company plans to subscribe 50 million yuan. The capital source of this investment is its own capital.
In accordance with the relevant laws and regulations such as the Listing Rules of Shenzhen Stock Exchange on the gem, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem and the articles of association, this investment is within the authority of the board of directors of the company and does not need to be submitted to the general meeting of shareholders for deliberation. This foreign investment does not constitute a connected transaction, nor does it constitute a major asset reorganization stipulated in the administrative measures for major asset reorganization of listed companies.
2、 Introduction to counterparty
1. Fund manager of the partnership: Shanghai Kangcheng Investment Management Co., Ltd
Enterprise type: joint stock limited company (unlisted, natural person investment or holding)
Unified social credit Code: 9131000031222622538
Registered address: Block C, 1f, No. 730-736, Qinghu Road, Qingpu District, Shanghai
Date of establishment: September 4, 2014
Registered capital: 10.018 million yuan
Business scope: investment management. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)
Mr. Sun Feng is the controlling shareholder, actual controller and legal representative of Shanghai Kangcheng Investment Management Co., Ltd. (hereinafter referred to as “Kangcheng investment”).
At present, Kangcheng investment mainly focuses on equity investment in the fields of life science and medical health. It has been registered as a private fund manager in China fund industry association with the registration code of p1008717.
2. General partner of the partnership: Tianjin Kangen enterprise management consulting partnership (limited partnership)
Enterprise type: limited partnership
Unified social credit Code: 91120116ma07hrph88
Address: 1-717, Chuangzhi building, No. 482, animation Middle Road, Zhongxin ecological city, Binhai New Area, Tianjin (No. 384 of Tianjin Zhirong Business Secretary Service Co., Ltd.)
Executive partner: Shanghai Kangcheng Investment Management Co., Ltd
Date of establishment: January 20, 2022
Registered capital: 10 million yuan
Business scope: general items: enterprise management consulting; Information consulting services (excluding licensed information consulting services). (except for the items that must be approved according to law, the company shall independently carry out business activities according to law with its business license)
The above two counterparties have no relationship or interest arrangement with the company, and they have no relationship or interest arrangement with the controlling shareholder, actual controller, shareholders holding more than 5%, directors, supervisors and senior managers of the company. The controlling shareholders, actual controllers, shareholders holding more than 5%, directors, supervisors and senior managers of the company do not participate in the subscription of the fund units and do not hold positions in the fund.
3、 Basic information of the partnership to be invested
1. Name of partnership: Tianjin Kangcheng Bain equity investment fund partnership (limited partnership)
2. Scale of the partnership: the scale of the capital to be raised by the partnership is 150 million yuan, and the company plans to subscribe 50 million yuan
3. General partner: Tianjin Kangen enterprise management consulting partnership (limited partnership)
4. Fund manager: Shanghai Kangcheng Investment Management Co., Ltd
5. Duration: the duration of the partnership is 7 years (the first 5 years are the investment period and the last 2 years are the exit period). 6. Investment direction: the partnership will focus on equity investment in the fields of life science and medical health
The above information shall be subject to the final partnership agreement and the information finally approved and registered by the administrative department for Industry and commerce. 4、 Main contents of investment agreement
At present, the company has not signed a partnership agreement with relevant parties, and the rights and obligations of all parties will be agreed in the partnership agreement. The company will timely perform the corresponding information disclosure obligations according to the follow-up progress.
5、 Purpose, existing risks and impact on the company of this investment
1. Purpose of this investment
The main investment direction of the partnership invested by the company this time is the equity investment related to the company’s main business, which can expand the company’s investment channels and obtain investment income in combination with the company’s professional advantages in the fields of life science and medical health. At the same time, this investment can effectively rely on the investment experience, professional ability and high-quality resources of professional investment institutions, explore and cultivate partners with complementary resources and strategic coordination with the company’s main business, constantly improve the industrial chain layout and enhance the company’s comprehensive competitiveness.
2. Existing risks
The agreement on this investment in the partnership has not been signed, and the investment fund has not yet fulfilled the registration and filing procedures, so there are certain uncertain factors. In the subsequent operation of the partnership, there may be many risk factors such as project implementation, risk control, uncertainty of investment income and exit. The company will disclose the progress of this investment in a timely manner in strict accordance with relevant regulations. Please pay attention to the investment risks.
3. Impact on the company
The establishment of the partnership is in line with the company’s strategic direction and actual business needs. This investment will not have a significant impact on the company’s financial situation and operating results in the short term.
6、 Documents for future reference
Resolution of the 13th meeting of the first board of directors. It is hereby announced.
Acrobiosystems Co.Ltd(301080) board of directors January 25, 2022
